Resultados de la búsqueda 221-230 of 11374 for Raised white cell count

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of increasing immune response and protecting against breast cancer.

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ... increased risk of secondary non- ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a peripheral blood Collection Protocol to study the T-cell ... high (80-90%) frequency of MUC1 ... count ≥ 1,500 /microliter, and platelets ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    This is a peripheral blood Collection Protocol to study the T-cell ... high (80-90%) frequency of MUC1 ... count ≥ 1,500 /microliter, and platelets ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a peripheral blood Collection Protocol to study the T-cell ... high (80-90%) frequency of MUC1 ... count ≥ 1,500 /microliter, and platelets ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

  8. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers.